Novavax Covid vaccine submitted to UK regulator for approval

The final data on the Novavax Covid vaccine has been submitted to the UK regulator for approval. The firm behind the vaccine said it anticipates a 'positive decision' following the completion of its rolling regulatory submission to the Medicines and Healthcare products Regulatory Agency (MHRA). More than 15,000 people took part in the phase 3 Novavax trial at various hospital sites across the UK. Novavax said its application for conditional marketing authorisation (CMA) marks the first submission for authorisation of a protein-based coronavirus vaccine in the UK.